RE:RE:RE:Acumen Pharmaceuticals IncRe PMN competition, Wren is the only one starting from the same place with their "Third generation in silico antibody design platform generates antibodies against any epitope of an intrinsically disordered protein."
Everyone else starts from some theory where protein misfolding is not the key step and opportunity.
And read their publication list for titles that sound like Cashman-Plotkin worthy subjects.